natgillin/translations-raw huggingface dataset:
In one aspect, the non-human animal described herein comprises a population of B cells in response to an antigen of interest that is enriched for antibodies that exhibit a decrease in dissociative half-life (t1/2) at an acidic pH as compared to neutral pH of at least about 2-fold, at least about 3-fold, at least about 4-fold, at least about 5-fold, at least about 10-fold, at least about 15-fold, at least about 20-fold, at least about 25-fold, or at least about 30-fold. In one embodiment, the decrease in t1/2 at an acidic pH as compared to a neutral pH is about 30 fold or more. 
Glodavac prema bilo kojem od prethodnih zahtjeva, naznačen time, što glodavac sadrži populaciju antitijela specifičnih za antigen koja je, u usporedbi s populacijom antitijela specifičnih za antigen dobivenih u glodavaca koji ne sadrže supstituirani histidinski kodon u varijabilnoj regiji imunoglobulinskog lakog lanca, obogaćena antitijelima specifičnim za antigen koja izražavaju smanjenje disocijativnog vremena poluraspada (t,,») pri kiseloj pH vrijednosti u usporedbi s neutralnom pH vrijednošću najmanje dvostruko, najmanje trostruko, najmanje četverostruko, najmanje petostruko, najmanje desetostruko, najmanje petnaestostruko, najmanje dvadesetostruko, najmanje dvadesetpetostruko, najmanje tridesetostruko ili opcionalno najmanje tridesetostruko ili veće.
A method of encapsulating at least one agent in silk fibroin, comprising: (i) contacting an aqueous silk fibroin solution with an ultrasonication treatment for a period of about 5 seconds to about 60 seconds to initiate gelation, wherein the power output of ultrasonication ranges from about 25% to about 55% amplitude, and wherein the silk fibroin is selected from the group consisting of silk produced by silkworms, silk produced by spiders and variants thereof; and 
Postupak kapsuliranja barem jednog sredstva u fibroin svile, obuhvaća: uvođenje sredst(a)va u otopinu fibroina svile; i dovođenje u doticaj otopine fibroina svile s obradom pomoću ultrazvukom kroz vrijeme od oko 5 sekundi do oko 60 sekundi radi započinjanja geliranja; kako bi se dobilo sredstvo kapsulirano u fibroinu svile.
optionally a nucleic acid represented by the sequence SEQ ID NO: 4 or a nucleic acid having a sequence identity of at least 85%, particularly 90%, in particular 95% with the sequence SEQ ID NO: 4, coding for the acetoacetate decarboxylase of C. acetobutylicum, and 
- < opcionalno nukleinsku kiselinu opisanu u sekvenci SEQ ID NO: 4 ili nukleinsku kiselinu koja ima identičnost sekvence od najmanje 85 %, naročito 90 %, posebno 95 % sa sekvencom SEQ ID NO: 4, koja kodira za acetoacetat dekarboksilazu od Ć. acetobutylicuma, 1
A method for treating an individual having the disease selected from Alzheimer's disease, depression, and schizophrenia, which comprises the steps of providing to said individual a therapeutically effective amount of a compound of formula (I) as defined in claim 1 . 
Spoj sa formulom (I) kako je definiran u zahtjevima 1 ili 2 naznačen time da je za uporabu kao lijek kod liječenja poremećaja središnjeg živčanog sustava koji je povezan sa ili uzrokovan sa 5-HT4 receptorom.
FIG. 2 shows the supra additive (synergistic) effect of phentermine and the selective 5HT-2C receptor agonist 8-Chloro-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (Cmpd A) on feeding in rats. 
Pripravak u skladu sa zahtjevom 1, naznačen time, da navedeni selektivni agonist 5HT-2C receptora je 8-kloro-7metoksi-1-metil-2,3,4,5-tetrahidro-1H-3-benzazepin ili njegova farmaceutski prihvatljiva sol, solvat i hidrat.
the length of L3 is at least twice the length of L1;and wherein the linkers provide sufficient mobility for pairing of VL1 and VH1, and for pairing of VL2 and VH2, and the first and second polypeptides form a cross-over light chain-heavy chain pair. 
L, je duljine 2 do 15 ostataka amino kiseline; i pri čemu prvi i drugi polipeptidi tvore prijelazni par laki lanac-teški lanac. Protutijelu sličan vezivni protein prema bilo kojem zahtjevu 5 ili 6, naznačen time da: L, je duljine 1 do 2 ostatka amino kiseline;
Peptide for use according to claim 1, wherein R3 and R4 are selected from the group consisting of H, methyl, ethyl, hexyl, dodecyl and hexadecyl. 
Peptid za uporabu prema zahtjevu 1, naznačen time što su R3 i Rx odabrani iz skupine koju čine H, metil, etil, heksil, dodecil i heksadecil.
a groove 177 on the front surface having a slightly larger than the upper edge 209 of the capsule 20; 
- utor 177 na prednjoj površini, blago širi od gornjeg ruba 209 kapsule 20;
CRL-9096] when expressed therein; introducing in the host cell at least one nucleic acid encoding at least a part of said protein; 
uvođenju u stanicu domaćina, koja je imortalizirana stanica iz ljudske krvi najmanje jedna nukleinska kiselina koja kodira u najmanju ruku dio navedenog proteina; i
The method according to claim 25, wherein following addition of 2-((1-methylpropyl)amino)ethanol to the suspension, the suspension is introduced in a container or unit up to a level determined by measurement of the suspension conductivity. 
18.Postupak u skladu s patentnim zahtjevom 17, naznačen time da se, nakon dodavanja navedenog 2-((1- metilpropiljamino)etanola u navedenu suspenziju, suspenzija dodaje u spremnik ili jedinicu do razine određene mjerenjem vodljivosti suspenzije.
The unit dosage forms are administered to a pregnant woman suffering from, or preventing, opiate abstinence syndrome. 
Jedinični oblici doziranja daju se trudnoj ženi, koja pati od, ili joj se sprječava, sindrom opijatne apstinencije.
The first polypeptide of claims 10 or 11, wherein the transmembrane domain is interposed between the first member of a specific binding pair and the first member of a dimerization pair. 
Prvi polipeptid u skladu s patentnim zahtjevom 10 ili 11, naznačen time, da je domena transmembrane umetnuta između prvog člana specifično vezujućeg para i prvog člana dimerizacijskog para.
A modified serpin according to any one of claims 1 to 8 wherein; the P4 residue in the RCL of the modified serpin is A, the P2 residue is K, and the P1' residue is K; 
Modificirani serpin prema bilo kojem od zahtjeva 1 do 8, naznačen time, da: ostatak P4 u RCL-petlji od modificiranog serpina je A, ostatak P2 je K; i ostatak P1' je K;
The pharmaceutical composition according to claim 1 wherein the brittle diluent is dibasic calcium phosphate. 
Farmaceutski pripravak u skladu sa zahtjevom 1, naznačen time, da je krhko otapalo dibazni kalcij fosfat.
A number of embodiments of the invention have been described. 
05.04.2017. Broj objave europskog patenta:
the trigger lever has one of a cranked angled peripheral contour. 
poluga okidača (6.1, 6.2) ima koljenastu perifernu konturu ili perifernu konturu pod kutom.
The cell of claim 12, wherein the cap, distribution, spreader and repeater disks are configured and arranged to distribute a first melt stream flowing in a first direction and a second melt stream flowing in a second direction opposite the first direction. 
Modul za ponavljanje niza slojeva u skladu s patentnim zahtjevom 12, naznačen time što su pokrovni (32, 34), razdjelnički (36), razmačni (38) i ponavljački (40) diskovi tako konfigurirani i smješteni da raspodjeljuju struju prve taline koja teče u prvom smjeru 1 struju druge taline koja teče u drugom smjeru, suprotnom prvom smjeru.
The composition of claim 13, wherein the viruses used as the source of the antigens are grown on cell culture (e.g. 
Pripravak prema zahtjevu 13, naznačen time da se virusi koji se koriste kao izvor antigena uzgajaju na staničnoj kulturi (tj.
A compound of formula (I) or a pharmaceutically acceptable salt, tautomer(s), solvate or polymorph thereof, wherein R1 is hydrogen, C1-4alkyl, cyclopropyl or C1-6alkoxy, halogen, hydroxyl, trifluoromethyl. 
Spoj formulom (I) ili njegova farmaceutski prihvatljiva sol, tautomer(i), solvat ili polimorf, naznačen time što je vodik, C1-4alkil, ciklopropil ili C1-6alkoksi, halogen, hidroksil, trifluorometil,.
measuring, in an area associated with the second group of power units (119), a frequency characteristic relating to a frequency of electricity flowing in the electric power grid (100); 
mjerenje u području povezanom s drugom skupinom mrežnih uređaja (119) frekvencijske karakteristike frekvencije protoka električne energije unutar energetske mreže (100);
Consistently, the median peak position (MPP) shifted on the frequency axis from 10 to 15-17 Hz and from 11 to 13-15 Hz. 
Konzistentno tome, medijalna pozicija maksimuma (MPP, prema engleskom:,,median peak position") pomak osi frekvencije iz 10 do 15-17 Hzi od 11 do 13-15 Hz.
The biomimetic compound for use according to claim 5 wherein the inflammatory disease is a disease selected from arthritis, multiple sclerosis, type I diabetes, autoimmune thyroiditis, idiopathic thrombocytopenic purpura, chronic inflammatory polyneuropathy, scleroderma, autoimmune uveitis, systemic lupus erythematosus, myasthenia gravis, and atopic dermatitis or a disease associated with the transplantation of an organ from a donor to a recipient; or an infectious disease a bacterial infection or a viral infection. 
Spoj biomimetika za uporabu prema zahtjevu 5, naznačen time, da se kod upalne bolesti radi o bolesti koja je odabrana od sljedećih: artritis, multipla skleroza, dijabetes tipa 1, autoimuni_ tiroiditis, idiopatska trombocitopenijska purpura, kronična upalna polineuropatija, skleroderma, autoimuni uvcitis, sustavna lupus eritematoza, miastenija gravis i atopijski dermatitis, ili bolest povezana s transplantacijom organa od davatelja za primatelja; ili zarazna bolest s bakterijskom infekcijom ili virusnom infekcijom.
The invention relates to a compound of formula 1 wherein 
Spoj, naznačen time, da je to spoj formule 1
A combination for use according to any one of claims 1 to 9 wherein folinic acid at a dosage of about 400 mg/m2, 5-fluorouracil (5-FU) at a dosage of about 2800 mg/m2, irinotecan at a dosage of about 180 mg/m2 and aflibercept at a dosage of about 4 mg/kg are administered to patient. 
Kombinacija za uporabu prema bilo kojem od zahtjeva 1 do 9 naznačena time da se pacijentu daje folinska kiselina u dozi od oko 400 mg/m2, 5-fluorouracil (5-FU) u dozi od oko 2800 mg/m2, irinotekan u dozi od oko 180 mg/m2 i aflibercept u dozi od oko 4 mg/kg.
A seed according to claim 17, wherein said sulfonylurea herbicide is selected from the group consisting of: chlorsulfuron, metsulfuron methyl, sulfometuron methyl, chlorimuron ethyl, thifensulfuron methyl, tribenuron methyl, bensulfuron methyl, nicosulfuron, ethametsulfuron methyl, rimsulfuron, triflusulfuron methyl, triasulfuron, primisulfuron methyl, cinosulfuron, amidosulfuron, flazasulfuron, imazosulfuron, pyrazosulfuron ethyl, halosulfuron, and mixtures thereof. 
Postupak prema zahtjevu 8, naznačen time, da je spomenuti sulfonilurea-herbicid odabran iz skupine koju čine: klorosulfuron, metsulfuron metil, sulfometuron metil, klorimuron etil, tifensulfuron metil, tribenuron metil, bensulfuron metil, nikosulfuron, etametsulfuron metil, rimsulfuron, triflusulfuron metil, triasulfuron, primisulfuron metil, kinosulfuron, amidosulfuron, flazasulfuron, imazosulfuron, pirazosulfuron etil, halosulfuron, te njihove mješavine.
The search space further includes a localised part of 1010 formed by the first and the second candidates with aggregation level four, by six candidates of aggregation level 2 and by another 6 candidates of aggregation level 1. 
Metoda prijema sukladno jednom od zahtjeva od 1 do 3, naznačena time da je prva vrijednost razine agregacije 2 1 da je druga vrijednost razine agregacije 4 ili 6.
cyclizing the trans-amino acid derivative of formula I or formula II, or a salt thereof, to give a lactam of formula IV or formula VII, 
Postupak dobivanja asenapina formule A ili njegove soli, naznačen time što se navedeni postupak sastoji u: (a) ciklizaciji trans-aminokiselinskog derivata formule I ili formule II
A compound having formula (I): 
Spoj formule (I): R4
The isolated molecule of claim 9, wherein said molecule comprises a 2'-O methyl phosphorothioate ribose. 
Oligonukleotid u skladu s patentnim zahtjevom 1, pri čemu je navedeni oligonukleotid 2'-O metil fosforotioat oligoribonukleotid.
Ar is selected from the group consisting of phenyl and thiophen-yl; is selected from the group consisting of unsubstituted imidazolyl, substituted imidazolyl, chloro, bromo, fluoro, hydroxy, and methoxy; 
R, je odabran iz skupine koju čine: vodik, C;-Cg alkil, C3-Cgcikloalkii, aril, supstituirani aril, heteroaril i supstituirani heteroaril, gdje su aril, heteroaril i supstituenti za aril i heteroaril prethodno definirani;
The method of claim 6, wherein the binding molecule is administered in combination with a chemotherapeutic drug or with radiotherapy, wherein the chemotherapeutic drug or the radiotherapy is administered prior to the binding molecule. 
Vežuća molekula koja se može vezati na L1, namijenjena upotrebi u skladu s patentnim zahtjevom 10, točka (ii), naznačena time što se kemoterapijski lijek ili radioterapija primjenjuje prije vežuće molekule.
1C and 1D provide the translation of the ORFs denoted in FIGS. 
(46) Datum objave prijevoda patentnih zahtjeva: 17.11.2017.
adding a solution of FeCl3 to the solution of (ii) at a temperature within the range of from 10 to 30°C; preferably, the amount of FeCl3 is in the range of from 30% wt.-% to 120% wt.-% of the amount of glucose syrup. 
dodavanje otopine FeCl3 otopini u skladu s korakom (ii) temperature unutar raspona od 10 do 30°C; količina FeCl3 raspona od 30% masenog udjela do 120% masenog udjela količine glukoznog sirupa.
From this perspective small particles are preferred. 
Iz ove perspektive preferiraju se sitne čestice.
providing or generating at least one candidate sequence which consists of an amino acid sequence modified by substituting, deleting, or adding one, two or several amino acid residues to an original amino acid sequence, wherein the original amino acid sequence is selected from the group consisting of SEQ ID NO: 344; 
osiguravanja najmanje jednog slijeda kandidata koji ima aminokiselinski slijed modificiran zamjenom jednog ili dva aminokiselinska ostatka u izvornom aminokiselinskom slijedu, gdje se izvorni aminokiselinski slijed se bira iz skupine koju čine SEQ ID NO:41, 44, 46, 48 i 78;
The compound for use according to claim 1, wherein R3 and R'3 together with the carbon atom to which they are attached form a C3-7 cycloaliphatic, in particular a cyclopropyl ring. 
N o] HI Spoj prema zahtjevu 1, naznačen time da R; i R's zajedno s atomom ugljika na koji su vezani tvore C3; cikloalifatski, naročito ciklopropilni prsten.
An immunogenic composition comprising an M72 related antigen, wherein the M72 related antigen comprises a sequence having at least 90% identity to SEQ ID No: 1, the pH of said composition is in the range 7.5 to 8.5, and the concentration of sodium chloride is 50 mM or lower. 
Imunogeni pripravak koji sadrži antigen povezan s M72, naznačen time što antigen povezan s M72 sadrži slijed koji je najmanje 90% istovjetan SEQ ID No: 1, pH navedenog pripravka je u rasponu od 7,0 do 9,0, a vodljivost pripravka je 5 mS/cm ili manja.
The method according to claim 11, wherein said malignant cells are cells from a tumor selected from the group consisting of a hematological tumor and a solid tumor. 
13. Uporaba prema zahtjevu 12, gdje su te maligne stanice iz tumora odabranog iz skupine koju čine hematološki tumor i solidni tumor.
A thermoplastic fabric made of heat resistant fibers or made of threads of heat resistant fiber, and impregnated with a composition comprising a mixture of a product A and a product B: 
HR P20191776 T1 PATENTNI ZAHTJEVI Termoplastična tkanina izrađena od vlakana otpornih na toplinu ili izrađena od niti vlakana otpornih na toplinu, impregnirana pripravkom koji sadrži smjesu proizvoda A i proizvoda B:
The effective filing date is the date of the earliest priority application disclosing the accession number in question. Unless otherwise apparent from the context any element, embodiment, step, feature or aspect of the invention can be performed in combination with any other. A PSD95 inhibitor for use in treating a damaging effect of ischemia on the central nervous system in a subject having or at risk of ischemia wherein reperfusion therapy is performed on the subject, and the PSD-95 inhibitor and reperfusion therapy treat a damaging effect of the ischemia on the central nervous system of the subject and wherein the reperfusion therapy comprises administration of a thrombolytic agent. 
Inhibitor PSD-95, naznačen time što je namijenjen upotrebi u liječenju oštećujućeg učinka ishemije na središnji živčani sustav kod ljudskog subjekta koji ima ili je u opasnosti od ishemije, gdje se reperfuzijsku terapiju provodi na subjektu, a inhibitor PSD-95 i reperfuzijska terapija liječe oštećujući učinak ishemije na središnji živčani sustav subjekta, gdje se inhibitor PSD-95 primjenjuje prije provođenja reperfuzijske terapije, gdje se reperfuzijsku terapiju provodi nakon određivanja ima li kod subjekta razloga za reperfuziju na osnovi ishemijske penumbre i nečitovanja krvarenja prilikom CT, MRI ili PET analize, te gdje inhibitor sadrži peptid koji ima aminokiselinski slijed koji se sastoji od ili sadrži KLSSIESDV (SEQ ID NO:5) ili KLSSIETDV (SEQ ID NO:43), gdje je peptid vezan na internalizirajući peptid ili je lipidiran, čime se pojačava prolazak peptida preko membrane ili krvno-moždane barijere.
is deoxygenated and is not bound to CO; 
Pripravak sukladno zahtjevu 1, pri čemu hemoglobin nije vezan za CO.
Group Number of rats 
Broj međunarodne objave:
Cancer cells replicate more rapidly than most other cells and so have a greater demand for nucleotides, the precursors of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). 
Stanica raka se repliciraju mnogo brže nego ostale stanice, i tako imaju veću potrebu z a nukleotidima, prekursorima deoksiribonukleinske kiseline (DNA) i ribonukleinske kiseline (RNA).
Thus Process A may involve taking the known isomers of dihydrotetrabenazine, dehydrating them to form the alkene (II) and then "rehydrating" the alkene (II) using conditions that give the required novel cis dihydrotetrabenazine isomers of the invention. 
Tako Postupak A može obuhvaćati uzimanje poznatih izomera dihidrotetrabenazina, njihovo dehidriranje do alkena (II) 1 zatim "rehidriranje" alkena (II) uporabom uvjeta koji daju traženi novi cis izomer dihidrotetrabenazina izuma.
As a result the contents of the container 3 come into contact with a shut-off valve 18 in the line 13. 
Kao rezultat sadržaj spremnika 3 dolazi u dodir s ventilom za zatvaranje 18 cijevi 13.
an NDV-F gene having the polynucleotide sequence set forth in SEQ ID NO: 1, operably linked to an SV40 promoter and an SV40 polyA signal and inserted into the IG1 locus of the HVT genome; or 
NDV-F-gen koji ima polinukleotidnu sekvencu prikazanu u SEQ ID BR:1, koji je operativno povezan s SV40 promotorom i SV40 poliA-signalom, i umetnut je u IG1 lokus od HVT genoma; ili
In certain embodiments, the composition is formulated for one of: intravenous administration, injectable administration, topical administration, systemic administration, aerosol administration to the respiratory epithelium, or oral administration. 
(i) pripravak je formuliran za jedno od: intravensko davanje, injekcijsko davanje, topikalno davanje, sistemsko davanje, inhalacijsku primjenu ili oralnu primjenu;
A pharmaceutical composition containing a compound of claim 1 or 2 and a pharmaceutically acceptable excipient. 
Farmaceutski pripravak koji sadrži spoj prema zahtjevu 1 i farmaceutski prikladnu pomoćnu tvar, ili farmaceutski pripravak koji sadrži spoj prema zahtjevu 16 i farmaceutski prikladnu pomoćnu tvar.
separating the trans-(−)-A9-tetrahydrocannabinol from the alcoholic-caustic phase; and 
(b) separaciju trans-(-)-A'-tetrahidrokanabinola od alkoholno-kaustične faze; i
Nutritional composition according to any one of claims 1-13 for use in improving body composition, the improvement of body composition being selected from the group consisting of increased lean body mass, decreased fat mass relative to total body weight, decreased visceral fat mass relative to total body weight, a decreased visceral fat mass relative to total fat mass, decreased fat accumulation and increased muscle mass, increased bone mass and increased bone mineral density. 
Nutritivni pripravak prema bilo kojem od zahtjeva 1-13 za uporabu u poboljšanju tjelesne građe, poboljšanje tjelesno građe se odabire iz skupine koju čine povećanje nemasnog dijela tjelesne težine, smanjenje masne težine u odnosu na ukupnu tjelesnu težinu, smanjenje tkivne masne težine tkiva u odnosu na ukupnu tjelesnu težinu, smanjenje tkivne masne težine tkiva u odnosu na ukupnu masnu težinu, smanjenje nakupljanja masti i povećanje mišićne mase, povećanje koštane mase i povećanje mineralne gustoće kostiju.
The solid formulation according to the invention may also comprise one or several disintegrants selected from the group consisting of croscarmellose sodium, sodium starch glycolate, pregelatinised starch, cross-linked polyvinylpyrrolidone and the like. 
Kruti pripravak prema bilo kojem od zahtjeva 2 do 6, naznačen time, da je dezintegrant odabran iz skupine koju čine kroskarmeloza-natrij, natrijev škrobni glikolat, predželatinizirani škrob i križno povezani polivinilpirolidon.
The method according to claim 10, including forming an opposite first dual circular curved hull outer surface area (12M) in mirror image of said first dual circular curved hull outer surface area (12) on an opposite side of the plane of symmetry (PS) from the first dual circular curved hull surface area (12). 
Postupak prema patentnom zahtjevu 10, naznačen time, da uključuje oblikovanje suprotne vanjske površine prvog dvostrukog kružno zakrivljenog trupa (12M) kao zrcalne slike navedene vanjske površine prvog dvostrukog kružno zakrivljenog trupa (12), na suprotnoj strani ravnine simetrije (PS) od prve vanjske površine dvostrukog kružno zakrivljenog trupa (12).
Unlocking the carbamate salt and starting the crosslinking reaction by heating the substrate. 
oslođbađanje karbamatne soli i početak reakcije umrežavanja zagrijavanjem supstrata.
The crude material is then purified to afford a compound of formula I. Examples of compound (8) include 2-thiophenemethyl amine, 4-hydroxybenzyl amine, and benzylamine. 
neeN 8) di i (c) reagiranje spoja (7) i spoja (8) čime se dobiva spoj formule I: č
human light chain framework regions, a light chain CDR1 comprising an amino acid sequence of SEQ ID NO:61, a light chain CDR2 comprising an amino acid sequence of SEQ ID NO:64, and a light chain CDR3 comprising an amino acid sequence of SEQ ID NO:66; and human heavy chain framework regions, a heavy chain CDR1 comprising an amino acid sequence of SEQ ID NO:63, a heavy chain CDR2 comprising an amino acid sequence of SEQ ID NO:65, and a heavy chain CDR3 comprising an amino acid sequence of SEQ ID NO: 67 or 68. 
Proizvodni artikl koji sadrži protein koji se specifično veže na CD20 i humanizirani protein koji se specifično veže na CD37 za upotrebu u liječenju karcinoma B-stanica ili autoimune bolesti, pri čemu humanizirani protein koji se specifično veže na CD37 sadrži: humane okvirne regije lakog lanca, laki lanac CDR1 koji sadrži aminokiselinski slijed iz SEQ ID NO:61, laki lanac CDR2 koji sadrži aminokiselinski slijed iz SEQ ID NO:64 i laki lanac CDR3 koji sadrži aminokiselinski slijed iz SEQ ID NO:66, i humane okvirne regije teškog lanca, teški lanac CDR1 koji sadrži aminokiselinski slijed iz SEQ ID NO:63, teški lanac CDR2 koji sadrži aminokiselinski slijed iz SEQ ID NO:65 i teški lanac CDR3 koji sadrži aminokiselinski slijed iz SEQ ID NO: 67 ili 68.
For example, ratios on the order of 40 grams of inoculant to 50 tons of harvested crop are typical. 
Tako su, na primjer, tipični odnosi reda veličine od 40 g inokulanta na 50 tona ubranih usjeva.
a biologically effective amount of the compound of claim 1 of the composition of claim 10; and a propellant. 
(a) biološki efikasnu količinu spoja iz Zahtjeva 1 ili smjesu iz Zahtjeva 10; i
A reconstituted surfactant according to claim 1, which comprises: 
Rekonstituirani surfakant prema patentnom zahtjevu 1, naznačen time da analog prirodnog surfakanta proteina SP- C jest